06.13.26 -- Cell & Gene Newsletter - Best Of May

At the 2026 @Philly Cell and Gene Therapy Annual Conference, Dr. Peter Marks highlighted how gene therapy science is surging ahead and called for smarter regulatory evolution to unlock treatments for thousands of rare disease patients.

The warning letter, issued to Purolea Cosmetics Lab, describes a manufacturer that used AI agents to generate drug product specifications. Here's why the outsourced pharma industry should take note.

What do the promises and uneven realities of cell and gene therapies add up to in the development and manufacturing outsourcing sector? According to a Towards Healthcare report, in 2025, the global CGT CDMO market grew to $8.2 billion. What of future predictions? Here's a detailed analysis.

Cell banking stands at the forefront of medical advancement. This guide delves into the steps involved in protecting these priceless resources, from cell collection and processing to storage and cell expansion.

Early, collaborative CDMO partnerships optimize complex AAV development, enhancing manufacturability and reducing risks to shorten timelines more effectively than traditional transactional models.

Identifying low-level adapter dimers is essential for sequencing success. Compare electrophoresis methods to see how different kits resolve small fragments and improve your quality control results.